直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 114819
著者
Kato, Yoshikane Kanaiso Hospital
板東, 浩 Kanaiso Hospital|Tokushima University KAKEN研究者をさがす
Matsuzaki, Sayuri Kanaiso Hospital
Waka, Shinnichi Kanaiso Hospital
キーワード
chronic kidney disease (CKD)
Metformin
Canagliflozin
erythropoiesis stimulating agent (ESA)
hypoxia-inducible factor (HIF)
資料タイプ
学術雑誌論文
抄録
The authors and colleagues have been involved in Non-Communicable Diseases (NCDs), especially including diabetes, chronic kidney disease (CKD) and hemodialysis. Some topics are described as possible therapy for CKD. (i) Metformin has inhibitory effect on cardiovascular events, and has an evidence for safe administration in mild to moderate renal impairment. (ii) Canagliflozin reduced moderately cardiovascular and renal outcomes across the primary and secondary prevention groups, from mega studies of CANVAS and CREDENCE. (iii) erythropoiesis stimulating agent (ESA) has been effective for improving anemia in HD for years. Some hypoxia-inducible factor (HIF) seems to be applied for clinical practice soon.
掲載誌名
Pharmacy and Pharmacology International Journal
ISSN
23736367
出版者
MedCrave Publishing
8
2
開始ページ
87
終了ページ
89
発行日
2020-04-15
権利情報
©2020 Kato et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系